Rybelsus Manufacturing, Supply & Shortage History

What Is Rybelsus and How Does It Work?

Rybelsus is the first oral GLP-1 receptor agonist approved for clinical use. It contains semaglutide, the same active molecule found in injectable Ozempic, reformulated into a tablet using a co-formulated absorption enhancer called SNAC. The 14 mg dose reduces HbA1c by approximately 1.4 percentage points from baseline in clinical trials, placing it broadly in line with injectable liraglutide 1.8 mg [1].

The GLP-1 Receptor Agonist Mechanism

Semaglutide binds the glucagon-like peptide-1 (GLP-1) receptor with 94% amino-acid homology to native human GLP-1 [2]. Receptor activation triggers three primary glucose-lowering effects: glucose-dependent insulin secretion, suppression of glucagon release, and delayed gastric emptying. Unlike sulfonylureas, the insulin-secretion effect is glucose-dependent, meaning it attenuates when plasma glucose normalizes, which substantially reduces hypoglycemia risk.

Semaglutide also crosses the blood-brain barrier to act on hypothalamic appetite-regulation centers, which accounts for the modest but measurable weight loss observed even at the 14 mg oral dose (approximately 4.4 kg in PIONEER-4 at 52 weeks) [1].

Why an Oral GLP-1 Is Pharmacologically Challenging

Peptides are digested in the stomach before reaching the small intestine. Native GLP-1 has a plasma half-life under two minutes because of dipeptidyl peptidase-4 (DPP-4) cleavage. Semaglutide's backbone was modified at positions 8 and 34 and fatty-acid conjugated to albumin to extend its half-life to approximately 165 hours for the subcutaneous form [3]. Even with that modification, oral bioavailability without a co-formulation aid is below 1%.

The SNAC Technology: How Rybelsus Achieves Oral Absorption

SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) is the absorption-enhancer that makes oral semaglutide possible. Each Rybelsus tablet contains 300 mg of SNAC alongside 3 mg, 7 mg, or 14 mg of semaglutide. Understanding SNAC is inseparable from understanding the supply constraints that emerged later, because the molecule requires highly controlled synthesis and tablet manufacture.

How SNAC Works at the Gastric Mucosa

SNAC raises local gastric pH in a small mucosal microenvironment near the dissolving tablet. This prevents enzymatic degradation of semaglutide. At the same time, SNAC transiently increases epithelial membrane fluidity, allowing transcellular absorption of intact semaglutide directly through the gastric mucosa rather than through the intestinal wall [4]. The result is an absolute bioavailability of roughly 0.4% to 1%, which sounds low but is sufficient to produce therapeutic plasma concentrations when the 14 mg dose is taken correctly.

The Strict Fasting Requirement and Its Clinical Relevance

Because SNAC's absorption window is narrow and food significantly dilutes the gastric micro-environment, patients must swallow Rybelsus with no more than 4 oz (120 mL) of plain water, at least 30 minutes before the first food, drink, or other oral medication of the day. The FDA label specifies this requirement explicitly [5]. In practice, non-adherence to the fasting condition is the single most common reason patients and providers report subtherapeutic response, and it has downstream implications for dose-escalation decisions that inflate perceived demand for higher strengths.

SNAC Synthesis and Why It Complicates Manufacturing Scale-Up

SNAC is not a standard pharmaceutical excipient. It requires multi-step organic synthesis, strict quality controls for residual solvents, and dedicated synthesis capacity. Novo Nordisk licenses SNAC from Emisphere Technologies (now a Novo Nordisk subsidiary). The integration of that supply chain internally reduced one external bottleneck, but scaling SNAC production alongside semaglutide active pharmaceutical ingredient (API) production represents two parallel capacity constraints rather than one.

Rybelsus Manufacturing: Sites, Process, and Scale

Novo Nordisk manufactures semaglutide API at its Kalundborg, Denmark facility, one of the largest insulin and peptide production sites in the world. Tablet formulation and packaging occur at additional Danish and international Novo Nordisk sites. The company does not publicly disclose all contract manufacturing organization (CMO) partners for Rybelsus, but SEC filings indicate capital expenditure exceeding DKK 25 billion (approximately USD 3.6 billion) between 2021 and 2024 to expand peptide API capacity across semaglutide products [6].

Fermentation-Based Peptide Synthesis

Semaglutide API production uses recombinant DNA technology in yeast fermentation, followed by multiple chromatographic purification steps. The full synthesis cycle from fermentation to purified API takes weeks, not days. Each batch must clear identity, purity, potency, and endotoxin testing before release. This long lead time means demand spikes cannot be answered quickly. Novo Nordisk announced in 2022 that it was hiring thousands of additional manufacturing staff and accelerating construction at Kalundborg and at its Hillerod and Chartres (France) facilities to meet combined Ozempic and Rybelsus demand.

Tablet Compression and SNAC Co-formulation

The tablet manufacturing step is more complex than standard compression because SNAC must be uniformly distributed with semaglutide at a mass ratio of roughly 300:1 (SNAC:drug). Any variation in blend uniformity directly affects absorption variability. Novo Nordisk uses a direct-compression process with strict in-process controls on hardness, friability, and dissolution rate. The 30-minute fasting requirement on the label exists partly because dissolution testing showed that even small volumes of co-administered liquid measurably alter SNAC release kinetics.

The PIONEER Trial Program: Clinical Evidence Shaping Demand

The PIONEER program comprises ten Phase 3 trials evaluating oral semaglutide across doses and comparators. Two trials are particularly relevant to the supply narrative because their results drove prescriber uptake and indirectly contributed to demand pressure.

PIONEER-4 (Lancet 2019)

PIONEER-4 (N=711) compared oral semaglutide 14 mg once daily with subcutaneous liraglutide 1.8 mg once daily and placebo over 52 weeks. Oral semaglutide produced a mean HbA1c reduction of 1.2 percentage points versus 1.1 percentage points for liraglutide (estimated treatment difference 0.1 percentage points; 95% CI -0.0 to 0.3; P<0.001 for non-inferiority) [1]. Weight loss was 4.4 kg with oral semaglutide versus 3.1 kg with liraglutide.

The authors concluded: "Oral semaglutide was non-inferior to subcutaneous liraglutide in reducing HbA1c and superior in reducing bodyweight" [1]. This head-to-head result, published in The Lancet in June 2019, validated the oral route and set expectations among endocrinologists that Rybelsus could serve as a true injectable alternative for patients with needle aversion.

PIONEER-6 (NEJM 2019): Cardiovascular Safety

PIONEER-6 (N=3,183) was the FDA-required cardiovascular outcomes trial for oral semaglutide. It demonstrated non-inferiority to placebo for the primary MACE endpoint (major adverse cardiovascular events) with a hazard ratio of 0.79 (95% CI 0.57 to 1.11) [7]. The trial was not powered to demonstrate cardiovascular superiority, unlike the SUSTAIN-6 trial for injectable semaglutide 0.5/1.0 mg. This distinction matters for prescribing in high-cardiovascular-risk patients where injectable semaglutide or dulaglutide may be preferred based on outcome data, influencing which GLP-1 product carries higher demand.

Rybelsus Supply and Shortage History: 2019 to 2025

Understanding the shortage timeline requires separating two overlapping stories: capacity constraints at Novo Nordisk, and the FDA's formal shortage classification process.

2019: Launch and Initial Supply Calibration

Rybelsus received FDA approval on September 20, 2019 [5]. Novo Nordisk launched the 3 mg and 7 mg doses first, with the 14 mg dose following in October 2019. Initial uptake was slower than projected. The COVID-19 pandemic in 2020 further dampened in-person prescribing. Supply exceeded demand through most of 2020 and 2021, and no shortage was reported during this period.

2022: Demand Acceleration Tied to Ozempic Visibility

By mid-2022, injectable semaglutide (Ozempic) had become the most-discussed drug on social media and in mainstream press, primarily because of weight-loss use in people without diabetes. Prescribers began turning to Rybelsus as an oral alternative, including some off-label prescribing for obesity. This shift was pharmacologically inexact because the 14 mg oral dose delivers a substantially lower systemic semaglutide exposure than the 1 mg injectable dose, but the prescriber behavior was real and it created demand that Novo Nordisk's existing tablet manufacturing capacity had not anticipated.

2023: FDA Shortage Listing and Novo Nordisk's Response

In 2023, the FDA added oral semaglutide to its drug shortage database. The agency's shortage database entry noted supply disruptions for the 3 mg, 7 mg, and 14 mg tablet strengths [8]. Novo Nordisk publicly stated it did not consider Rybelsus to be in shortage in the United States and attributed intermittent pharmacy-level stockouts to distribution irregularities rather than true manufacturing deficits.

This tension between FDA classification and manufacturer characterization reflects a recurring pattern in the GLP-1 shortage era: the FDA shortage database operates on pharmacy-reported inability to source product, whereas manufacturers report based on wholesale shipment volumes, which can appear adequate even when individual pharmacies face weeks-long waits.

2024: Partial Resolution and Persistent Spot Shortages

Through 2024, Novo Nordisk increased Rybelsus production alongside expanded Ozempic and Wegovy manufacturing. The 7 mg and 14 mg strengths experienced the most persistent availability issues, partly because patients escalating from 3 mg created a demand concentration at higher doses. The 3 mg starter dose was generally more available because fewer patients remain on it long-term.

By Q3 2024, wholesaler-level data indicated that 14 mg tablets were available in most regional markets, though individual pharmacy restocking lag meant that patients and providers still reported difficulty in some geographic areas. The FDA's shortage database updated the Rybelsus entry multiple times during this period, reflecting a fluid situation.

2025: Current Availability Assessment

As of the date of this article's last review (July 2025), Rybelsus is not listed as an active shortage on the FDA drug shortages database for most strengths, though providers should verify current status directly through the FDA shortage database or their pharmacy wholesaler before prescribing [8]. Novo Nordisk's 2024 annual report noted total semaglutide sales across all formulations exceeded DKK 232 billion (approximately USD 33 billion), reflecting the scale of production now required to meet global demand.

Clinical Decision Framework: Rybelsus vs. Injectable Semaglutide in the Context of Supply

When a patient needs semaglutide and one formulation is unavailable, the substitution is not dose-for-dose. Oral semaglutide 14 mg once daily produces a mean steady-state AUC roughly 75% lower than subcutaneous semaglutide 0.5 mg once weekly [9]. A provider switching a patient from Ozempic 1 mg weekly to Rybelsus 14 mg daily should counsel the patient to expect attenuated glycemic and weight effects, and should plan a follow-up HbA1c check at 12 weeks to reassess. The reverse transition, moving from Rybelsus to injectable semaglutide because of tablet unavailability, requires confirming that the injectable supply is secure before discontinuing the oral supply chain.

Why Oral Peptide Manufacturing Is Harder Than Injectable Peptide Manufacturing

The manufacturing complexity of Rybelsus exceeds that of Ozempic on a per-unit basis, which helps explain why supply has been harder to expand rapidly.

API Mass Per Dose Is Similar, But Co-formulation Complexity Is Higher

Ozempic 1 mg weekly is administered as approximately 1 mg of semaglutide per week (depending on dose pen). Rybelsus 14 mg daily delivers 14 mg of semaglutide per tablet times seven tablets per week, or 98 mg weekly, to achieve a lower systemic exposure due to the approximately 1% bioavailability. The total semaglutide API consumed per patient per week is therefore roughly 98 times higher for the oral route than the injectable route for equivalent glycemic outcomes [9]. This mass differential is the single largest factor in Rybelsus manufacturing cost and capacity consumption per patient treated.

Quality Control Burden

Each tablet batch requires dissolution testing, content uniformity testing for both semaglutide and SNAC, and stability testing at accelerated conditions. Because SNAC is a novel excipient without a long pharmacopeial history, Novo Nordisk maintains proprietary specifications that require dedicated analytical method validation for each site that manufactures the product. Transferring manufacturing to a new site or CMO takes 18 to 36 months under standard regulatory timelines.

Regulatory History and Label Changes

The FDA approved Rybelsus under NDA 213051. Post-marketing commitments included the completed PIONEER-6 cardiovascular outcomes trial and ongoing pediatric studies. The label has been updated since 2019 to include additional safety information on acute pancreatitis, thyroid C-cell tumor risk (a class-wide GLP-1 warning based on rodent data), and diabetic retinopathy. No label change has directly addressed the supply disruptions.

The European Medicines Agency (EMA) approved oral semaglutide under the trade name Rybelsus in April 2020 [10]. Regulatory filings in Japan and Canada followed. The existence of multiple regulatory markets requiring independent batch release creates additional scheduling complexity for Novo Nordisk's manufacturing operations.

Clinical Implications for Prescribers During Supply Disruptions

Switching Protocols

If Rybelsus 14 mg is unavailable, the American Diabetes Association's 2024 Standards of Care do not specify a preferred switching protocol for intra-class GLP-1 substitution, but the pharmacokinetic differences above mean that injectable semaglutide 0.5 mg weekly is a reasonable starting point for a patient moving from oral semaglutide 14 mg, with titration to 1 mg at 4 weeks based on tolerability and glycemic response [11].

Counseling Points During Shortages

Patients on Rybelsus who experience a supply interruption of more than 7 days should be counseled to restart at 7 mg rather than 14 mg to minimize gastrointestinal side effects from re-exposure, consistent with standard GLP-1 re-titration practice. There is no published data from a named trial specifically on Rybelsus re-titration after gap, but GLP-1 class pharmacology supports this conservative approach.

Documentation for Prior Authorization During Shortage Periods

During shortage periods, some insurers have required additional documentation to approve injectable semaglutide as a bridge for patients whose Rybelsus supply was interrupted. Providers should document the FDA shortage database status at the time of prescribing, the patient's current Rybelsus dose and duration, and the clinical rationale for the specific injectable dose requested. The American Association of Clinical Endocrinology (AACE) published a GLP-1 shortage guidance statement in 2023 recommending that payers waive step-therapy requirements during periods of active FDA-designated shortage [12].

According to the AACE 2023 guidance document: "Insurers should recognize FDA-designated drug shortages as a sufficient clinical justification for prescribing an alternative within the same drug class without requiring additional step-therapy documentation" [12].

What Novo Nordisk Has Announced About Future Supply

Novo Nordisk's 2024 capital markets communications included commitments to add semaglutide API capacity equivalent to more than doubling 2022 output by 2026. The Kalundborg site expansion, referred to internally as the "Fill and Finish" expansion, focuses primarily on injectable formats for Ozempic and Wegovy, but the Hillerod facility expansion includes dedicated tablet manufacturing lines for Rybelsus.

The company also acquired three fill-and-finish manufacturing sites through its 2023 acquisition of contract manufacturer Catalent at a deal value of approximately USD 11 billion, giving it additional production flexibility. How much of that capacity will be allocated to oral semaglutide versus injectable formats depends on commercial demand trajectories that Novo Nordisk has not publicly specified.

An oral semaglutide formulation with higher bioavailability is in development. Novo Nordisk's OW (once-weekly) oral semaglutide candidate, currently in Phase 3 trials as of 2024, uses a next-generation absorption technology. If approved, it may eventually replace or supplement the SNAC-based Rybelsus formulation, though the regulatory and manufacturing timeline for a new oral formulation places any such transition well past 2027.